Alan J Korman

USPTO Granted Patents = 87 (Patent Applications = 54)

CIPO Patents = 8 (Patent Applications = 14)

EPO Patents = 21 (Patent Applications = 35)

Average Co-Inventor Count = 7.1

ph-index = 21

Forward Citations = 3,495(Granted Patents)

Forward Citations (Not Self Cited) = 3,178(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Piedmong, CA (US) (2019)
Piedmont, CA (US) (2006 - 2024)

Company Filing History:

43 out of 3,684

Bristol-myers Squibb Compnay

patents

24 out of 1,624

E. R. Squibb Sons, Inc.

Ono Pharmaceutical Co., Ltd.

patents

5. 6 out of 71

Five Prime Therapeutics, Inc.

patents

6. 1 out of 12

Biosante Pharmaceuticals, Inc.

Providence Health & Services

patents

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

Antibodies Binding to ILT4

Antibodies Against TIM3

Antibodies Binding to VISTA

Anti-CD27 Antibodies

NKG2A Protein

Anti-GITR Antibodies

Human Monoclonal Antibodies

Lymphocyte Activation Gene-3

Anti-ICOS Agonist Antibodies

Predictive Biomarkers

Cancer Diagnostics

Tumor Immunotherapy

87 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435136 - Antibodies binding to ILT4 (2025-10-07),

2. 12312403 - Antibodies against TIM3 and uses thereof (2025-05-27),

3. 12195535 - Antibodies binding to VISTA at acidic pH (2025-01-14),

4. 12173069 - Antibodies binding to vista at acidic pH (2024-12-24),

5. 12129297 - Antibodies against TIM3 and uses thereof (2024-10-29),

6. 12110337 - Anti-CD27 antibodies and uses thereof (2024-10-08),

7. 12091462 - Antibodies binding to vista at acidic pH (2024-09-17),

8. 12077584 - Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A) (2024-09-03),

9. 11981734 - Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A) (2024-05-14),

10. 11802162 - Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof (2023-10-31),

11. 11603406 - Antibodies binding to VISTA at acidic pH (2023-03-14),

12. 11591392 - Antibodies against TIM3 and uses thereof (2023-02-28),

13. 11530267 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-12-20),

14. 11529399 - Anti-ICOS agonist antibodies and uses thereof (2022-12-20),

15. 11512130 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-11-29),

Title: The Innovative Journey of Alan J Korman

Introduction: Alan J Korman, a pioneering inventor hailing from Piedmont, CA (US), has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Alan J Korman's latest patents showcase his ingenuity and forward-thinking approach to innovation, with a focus on cutting-edge technologies in the realm of artificial intelligence and renewable energy.

Career Highlights: Throughout his illustrious career, Alan J Korman has been at the forefront of technological advancements, with a keen eye for identifying gaps in the market and developing innovative solutions to address them. His work has not only revolutionized industries but has also inspired a new generation of inventors to push the boundaries of what is possible.

Collaborations: Alan J Korman's collaborative spirit has led to fruitful partnerships with leading tech companies and research institutions, where his expertise has been instrumental in driving forward projects that have the potential to shape the future of technology.

Conclusion: Alan J Korman's unwavering dedication to innovation, coupled with his passion for creating solutions that have a positive impact on society, solidifies his position as a trailblazing inventor whose work will continue to influence the technological landscape for years to come.

This text is generated by artificial intelligence and may not be accurate.